Background Adverse childhood experiences (ACEs) are linked to poor health and social outcomes, with growing interest in their ...

Merck’s enlicitide decanoate significantly reduced LDL-C in adults with heterozygous familial hypercholesterolemia in phase 3 CORALreef HeFH trial: Rahway, New Jersey Tuesday, N ...

Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 ...

Merck , known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with ...

A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who ...

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic ...

A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the ...

Understanding technical aspects like cloud security and encryption is increasingly important for modern privacy roles. Strong ...

Background Hypothyroidism has been suggested as a predisposing and prognostic factor in patients with spontaneous coronary ...

Background Guidelines strongly recommend reperfusion therapy, including thrombolysis and percutaneous coronary intervention, ...